We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The University of Oxford is ready to launch a phase 3 trial in Brazil of AstraZeneca (AZ)’s COVID-19 vaccine candidate, considered by the World Health Organization (WHO) to be the frontrunner in the research race. Read More
The vaccine candidate is stable at room temperature, which offers “an enormous logistical advantage in large vaccination campaigns,” the company said. Read More
China has approved phase 1 trials of a COVID-19 vaccine candidate being developed by the country’s military in collaboration with two Chinese companies. Read More
The World Health Organization (WHO) has unveiled a plan to deliver 2 billion doses of COVID-19 vaccines to low- and middle-income countries by the end of 2021, but says it needs almost $28 billion to help fund the initiative, which also includes therapeutics and diagnostics. Read More
AstraZeneca released full results from a phase 3 trial of its triple combination inhaled therapy Breztri Aerosphere in moderate to severe chronic obstructive pulmonary disease (COPD) patients, finding that it significantly reduced the rate of flare ups compared to two other combination treatments. Read More
New York-based BrainStorm Cell Therapeutics is launching a phase 2 trial of an investigational stem cell treatment for Alzheimer’s disease, using cells derived from patients’ bone marrow. Read More
Fulcrum Therapeutics has begun a phase 3 clinical trial in the U.S. of its investigational anti-inflammatory drug losmapimod for the treatment of hospitalized COVID-19 patients. Read More
RSS
